Clinical Trial Detail

NCT ID NCT03064854
Title PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Paclitaxel + Spartalizumab

Cisplatin + Pemetrexed + Spartalizumab

Cisplatin + Gemcitabine + Spartalizumab

Carboplatin + Cisplatin + Pemetrexed + Spartalizumab

Age Groups: adult senior

Additional content available in CKB BOOST